Home treatment of COPD exacerbation selected by DECAF score: A non-inferiority, randomised controlled trial and economic evaluation

Carlos Echevarria, Joanne Gray, Tom Hartley, John Steer, Jonathan Miller, A. John Simpson, G. John Gibson, Stephen C. Bourke

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
23 Downloads (Pure)

Abstract

BACKGROUND Previous models of Hospital at Home (HAH) for COPD exacerbation (ECOPD) were limited by the lack of a reliable prognostic score to guide patient selection. Approximately 50% of hospitalised patients have a low mortality risk by DECAF, thus are potentially suitable.

METHODS In a non-inferiority randomised controlled trial, 118 patients admitted with a low-risk ECOPD (DECAF 0 or 1) were recruited to HAH or usual care (UC). The primary outcome was health and social costs at 90 days.

RESULTS Mean 90-day costs were £1016 lower in HAH, but the one-sided 95% CI crossed the non-inferiority limit of £150 (CI -2343 to 312). Savings were primarily due to reduced hospital bed days: HAH=1 (IQR 1-7), UC=5 (IQR 2-12) (P=0.001). Length of stay during the index admission in UC was only 3 days, which was 2 days shorter than expected. Based on quality-adjusted life years, the probability of HAH being cost-effective was 90%. There was one death within 90 days in each arm, readmission rates were similar and 90% of patients preferred HAH for subsequent ECOPD.

CONCLUSION HAH selected by low-risk DECAF score was safe, clinically effective, cost-effective, and preferred by most patients. Compared with earlier models, selection is simpler and approximately twice as many patients are eligible. The introduction of DECAF was associated with a fall in UC length of stay without adverse outcome, supporting use of DECAF to direct early discharge.
Original languageEnglish
Pages (from-to)713-722
Number of pages10
JournalThorax
Volume73
Issue number8
Early online date21 Apr 2018
DOIs
Publication statusPublished - 1 Aug 2018

Fingerprint

Dive into the research topics of 'Home treatment of COPD exacerbation selected by DECAF score: A non-inferiority, randomised controlled trial and economic evaluation'. Together they form a unique fingerprint.

Cite this